1 / 11

MAIN-COMPARE Study

MAIN-COMPARE Study. Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease. MAIN-COMPARE Study. MAIN-COMPARE Study. Presented at ACC / i2 2008 in Chicago Presented by Dr. Seung-Jung Park. Copyleft Clinical Trial Results. You Must Redistribute Slides.

ainsley
Download Presentation

MAIN-COMPARE Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease

  2. MAIN-COMPARE Study MAIN-COMPARE Study Presented at ACC / i2 2008 in Chicago Presented by Dr. Seung-Jung Park Copyleft Clinical Trial Results. You Must Redistribute Slides

  3. MAIN-COMPARE Study: Background • Coronary artery bypass graft (CABG) surgery has been regarded as the standard of care in LMCA disease. • Early trials of LMCA disease treatment with drug eluting stents (DES) suggest promising outcomes with respect to mortality. Presented at SCAI-i2 summit 08

  4. MAIN-COMPARE Study: Study Design 2240 patients with unprotected left main artery disease, excluding those with prior CABG, valvular & aortic surgery, STEMI, or cardiogenic shock Prospective. Non-randomized. Observational. 49% underwent stent implantation and 51% underwent CABG surgery R Stent implantation n=1102 CABG surgery n=1138 R DES n=784 BMS n=318 1017 days median follow-up 1152 days median follow-up • Primary Endpoint: Death; the composite of death, Q-wave myocardial infarction or stroke; target vessel revascularization (TVR). Presented at SCAI-i2 summit 08

  5. MAIN-COMPARE Study: Baseline Characteristics Copyleft Clinical Trial Results. You Must Redistribute Slides Presented at SCAI-i2 summit 08

  6. MAIN-COMPARE Study: Angiographic Characteristics Copyleft Clinical Trial Results. You Must Redistribute Slides Presented at SCAI-i2 summit 08

  7. MAIN-COMPARE Study: EndpointsOverall cohort HR is risk of stenting in excess of CABG Copyleft Clinical Trial Results. You Must Redistribute Slides Presented at SCAI-i2 summit 08

  8. MAIN-COMPARE Study: EndpointsBMS vs. CABG HR is risk of stenting in excess of CABG Copyleft Clinical Trial Results. You Must Redistribute Slides Presented at SCAI-i2 summit 08

  9. MAIN-COMPARE Study: EndpointsDES vs. CABG Copyleft Clinical Trial Results. You Must Redistribute Slides Presented at SCAI-i2 summit 08

  10. MAIN-COMPARE Study: Limitations • This was a non-randomized, observational study, thus the results may have been influenced by confounders. • Additionally, a larger sample size is needed to appropriately power the study in order to detect significant differences in mortality. Presented at SCAI-i2 summit 08

  11. MAIN-COMPARE Study: Summary • The results of this study suggest that there is no significant difference in the mortality rate or the composite risk of death, Q-wave MI or stroke among patients with unprotected LMCA disease who undergo PCI vs. CABG. • However, CABG was associated with significant reduction in the incidence of target vessel revascularization compared to PCI. Presented at SCAI-i2 summit 08

More Related